13.07.2016 • NewsAgrochemistryCFIUSChemChina

ChemChina Extends Syngenta Offer to September

(c) Syngenta
(c) Syngenta

ChemChina has again extended, this time until Sept. 13, its $43 billion tender offer for all publicly held registered shares of Swiss agrochemicals giant Syngenta as well as all outstanding American depositary shares representing common shares.

This is the second extension for the Chinese company as it awaits regulatory clearance from authorities in the EU and the US – the previous deadline was Jul. 18. The company has reserved the right to extend the deadline again if circumstances require, but said it continues to expect to conclude transaction by end of year.

According to its offer prospectus, ChemChina may continue to extend the main offer period until Nov. 23, if regulatory approval has not been granted, as the terms requires that at least 67% of Syngenta’s shares be tendered for the transaction to conclude.

The toughest scrutiny is expected from the Committee on Foreign Investment in the United States (CFIUS). ChemChina and Syngenta voluntarily initiated a review by CFIUS following their announcement of the proposed merger in February, but the deal faces opposition in the US Congress.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.